Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival

Table 1 Correlation between RASSF6 expression and clinicopathological characters in patients with pancreatic ductal adenocarcinoma

Parameter	Total	RASSF6	RASSF6	RASSF6	P value
	n = 96	negative	weak	positive
		n = 51	n = 29	n = 16
Age (yr)					0.115
mean (range)	60.7 (31-77)	59.3 (77-45)	61.3 (31-77)	64.3 (54-70)
Gender					0.563
Male	51	29	13	9
Female	45	22	16	7
Location of tumor					0.777
Head	81	42	22	13
Body/tail	15	9	7	3
Differentiation					0.138
Well	35	14	11	10
Moderate	37	22	12	3
Poor	24	15	6	3
Tumor diameter (cm)					0.613
mean (range)	3.7 (1.5-8.0)	3.8 (1.5-8.0)	3.5 (1.5-6.0)	3.9 (7.5-5.5)
UICC/TNM stage					0.200
pI	6	4	0	2
pII	90	47	29	14
T-stage					0.0471, 0.0762
pT1	5	3	2	0
pT2	10	3	2	5
pT3	81	45	25	11
N-stage					0.124
pN0	35	23	9	3
pN1	61	28	20	13
Portal vein invasion					0.698
Negative	84	45	26	13
Positive	12	6	3	3
Perineural invasion					0.026
Negative	31	11	11	9
Positive	65	40	18	7
Surgical margins					0.694
Negative	79	43	24	12
Positive	17	8	5	4

¹Pearson’s χ² test;

²Fisher’s exact test. All other P values were obtained by Pearson’s χ² test.

Table 2 Potential predictors of overall survival in 96 patients with pancreatic ductal adenocarcinoma undergoing radical surgery

Variable	Univariate		Multivariate
	P value	HR	95%CI	P value
Tumor diameter	0.010	1.172	0.992-1.385	0.062
T stage	0.012	2.355	1.413-3.925	0.031
Differentiation	0.016	2.397	1.665-3.451	< 0.001
Perineural invasion	0.076	2.236	1.163-4.300	0.016
Rassf6 expression	0.021	4.620	2.027-10.527	0.006

HR: Hazard ratio; CI: Confidence interval.